Fatty liver disease medication may have no effect

A new randomized, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease (FLD) lose weight, nor does it improve their liver enzymes or insulin resistance. These findings are in the January issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

Read the whole article on Physorg

More from Physorg